The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells by Opydo-Chanek, Małgorzata et al.
PRECLINICAL STUDIES
The pan-Bcl-2 inhibitor obatoclax promotes
differentiation and apoptosis of acute myeloid leukemia cells
Małgorzata Opydo-Chanek1 & Iwona Cichoń1 & Agnieszka Rak2 & Elżbieta Kołaczkowska1 & Lidia Mazur1
Received: 4 January 2020 /Accepted: 26 March 2020
# The Author(s) 2020
Summary
One of the key features of acute myeloid leukemia (AML) is the arrest of differentiation at the early progenitor stage of
myelopoiesis. Therefore, the identification of new agents that could overcome this differentiation block and force leukemic cells
to enter the apoptotic pathway is essential for the development of new treatment strategies in AML. Regarding this, herein we
report the pro-differentiation activity of the pan-Bcl-2 inhibitor, obatoclax. Obatoclax promoted differentiation of human AML
HL-60 cells and triggered their apoptosis in a dose- and time-dependent manner. Importantly, obatoclax-induced apoptosis was
associated with leukemic cell differentiation. Moreover, decreased expression of Bcl-2 protein was observed in obatoclax-treated
HL-60 cells. Furthermore, differentiation of these cells was accompanied by the loss of their proliferative capacity, as shown by
G0/G1 cell cycle arrest. Taken together, these findings indicate that the anti-AML effects of obatoclax involve not only the
induction of apoptosis but also differentiation of leukemic cells. Therefore, obatoclax represents a promising treatment for AML
that warrants further exploration.
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Abbreviations
AML acute myeloid leukemia
Annexin V-FITC fluoresceinated annexin V
ATRA all-trans-retinoic acid
Bcl-2 B cell lymphoma 2
Bcl-xL B cell lymphoma extra-large
Bcl-w Bcl-2-like protein 2
Bax Bcl-2-associated X protein
Bak Bcl-2-associated killer
BH Bcl-2 homology domain
DMSO dimethyl sulfoxide
Mcl-1 myeloid cell leukemia-1
NBT nitro blue tetrazolium
OBAT obatoclax
PI propidium iodide
PMA phorbol 12-myristate 13-acetate
Introduction
Acute myeloid leukemia (AML) is a hematological malignan-
cy in which the bone marrow is replaced by a clonal popula-
tion of abnormal myeloid progenitors [1]. Themajor feature of
AML is differentiation arrest of these progenitor cells at early
stages of myelopoiesis. This is further accompanied by en-
hanced cell proliferation and resistance to death-inducing sig-
nals. Therefore, AML is a disorder of impaired hematopoietic
cell differentiation and apoptosis. Therapies aimed at resum-
ing the process of maturation and apoptosis in leukemic cells
are currently the most promising anti-AML strategies [1].
Treatment of acute promyelocytic leukemia (APL), a subtype
of AML, with all-trans-retinoic acid (ATRA) was the first
model of differentiation-targeted therapy [2]. Despite its spec-
tacular clinical success, ATRA-based therapy has limitations
due to both the induction of potentially life-threatening toxic-
ity and the acquisition of resistance in some patients [3].
Moreover, most non-APL AML patients do not benefit from
ATRA therapy. Therefore, the search for new compounds that
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can efficiently and selectively induce differentiation and apo-
ptosis in leukemic cells remains essential for the future of
AML therapy, especially concerning non-APL subtypes of
AML.
Recently, proteins of the B cell lymphoma-2 (Bcl-2) family
have attracted considerable interest as therapeutic targets in
AML [4–6]. The Bcl-2 protein family is a key regulator of
the mitochondrial pathway of apoptosis. Based on structural
and functional features, three different subclasses of the Bcl-2
protein family are distinguished. Proteins of the anti-apoptotic
Bcl-2 subfamily, such as Bcl-2, Bcl-xL and Mcl-1, inhibit
apoptosis by preserving mitochondrial membrane integrity
[7]. These proteins bind to and inactivate Bax and Bak, the
multidomain members of the pro-apoptotic subfamily. In re-
sponse to apoptotic signals, Bax and/or Bak undergo confor-
mational changes and oligomerize, forming pores in the outer
mitochondrial membrane. Mitochondrial membrane perme-
abilization leads to the release of death-promoting proteins
and, consequently, activation of the initiator caspase 9 and
effector caspases 3 and 7, resulting in the morphological and
biochemical changes associatedwith apoptosis [8]. Proteins of
the third subfamily, named “BH3-only” proteins, carry out
their pro-apoptotic function through twomechanisms: neutral-
ization of the anti-apoptotic Bcl-2 subfamily proteins and di-
rect activation of the pro-apoptotic effectors Bax and Bak [7,
8]. The balance between anti-apoptotic and pro-apoptotic
members of the Bcl-2 family, mediated through protein-
protein interactions, determines cell survival or death.
Besides being important regulators of apoptosis, proteins
of the Bcl-2 family also govern other cellular pathways, in-
cluding the cell cycle, proliferation and differentiation [9, 10].
Several studies have shown that Bcl-2 proteins are expressed
in early hematopoietic progenitors and regulated during the
differentiation of myeloid cells [11]. Moreover, there is
mounting evidence that the balanced regulation of Bcl-2 pro-
teins is crucially important in the generation, maintenance and
function of the hematopoietic system [12–14]. Importantly,
the expression of Bcl-2 and/or other members of the anti-
apoptotic subfamily is often elevated in hematological malig-
nancies, either as a result of gene translocations or amplifica-
tions, or due to mechanisms independent from genomic aber-
rations [15]. The over-expression of anti-apoptotic Bcl-2 fam-
ily members contributes to enhanced leukemic cell survival,
chemoresistance and poor clinical outcomes, suggesting that
these proteins may be an attractive therapeutic target [16–18].
Obatoclax, a synthetic indole bipyrrole derivative of bacte-
rial prodiginines, is a small-molecule inhibitor of the anti-
apoptotic proteins of the Bcl-2 family that was designed to
mimic pro-apoptotic BH3-only proteins in binding to anti-
apoptotic Bcl-2 family members. Obatoclax antagonizes
Bcl-2, Bcl-xL, Bcl-w andMcl-1, thus leading to the activation
of Bax/Bak, mitochondrial depolarization, cytochrome c re-
lease and subsequent activation of caspase-3, which
consequently leads to apoptosis in cancer cells [19, 20].
Moreover, obatoclax enhances apoptosis when combinedwith
conventional chemotherapeutics or targeted therapy drugs, as
has been shown in preclinical in vitro and in vivo studies [21,
22]. Several phase I and II clinical trials have been completed
investigating the use of obatoclax as a single agent in the
treatment of solid tumors and hematological malignancies,
including AML, chronic lymphocytic leukemia, acute lym-
phoblastic leukemia, myelodysplastic syndrome and
Hodgkin’s lymphoma, however, all of these trials demonstrat-
ed only modest efficacy [23]. Additionally, evidence from
clinical trials has indicated that obatoclax may be more effec-
tive when used in combination with other anti-cancer thera-
peutics, however further studies are required to fully investi-
gate this issue [23, 24]. Despite the clinical developments
regarding obatoclax, its anti-cancer activity is still not fully
understood. Recent investigations have highlighted additional
mechanisms behind obatoclax’s anti-cancer actions, including
the inhibition of proliferation and migration of colorectal [25]
and esophageal [26] cancer cells. Initial studies have shown
that obatoclax is capable of exerting anti-AML effects through
the induction of cell cycle arrest and inhibition of leukemic
cell growth [19, 27, 28]. Further elucidation of obatoclax’s
mechanism of action may provide important data in regard
to improving its therapeutic applications.
To our knowledge, thus far, the pro-differentiating effect of
obatoclax on AML cells has not been investigated. Therefore,
the present study was designed to determine the anti-AML
efficacy of obatoclax by examining its influence on differen-
tiation and apoptosis in human AML HL-60 cells. The HL-60
cell line has been widely applied in studies on hematopoietic
cell proliferation, differentiation and death [29, 30]. This cell
line was derived from a 36-year-old woman who was initially
considered to have APL, although subsequent evaluation has
indicated that the leukemia from which HL-60 cells were de-
rived is more appropriately classified as AMLwithmaturation
[29]. HL-60 cell cultures comprise maturation-arrested cells
with properties similar to those of myeloblasts and
promyelocytes, such as their characteristic large, rounded nu-
clei containing two to four distinct nucleoli, fine chromatin
and a basophilic cytoplasm with azurophilic granules [29].
These cells can be induced to differentiate in vitro into cells
of diverse myeloid lineages, depending on which reagents are
used. Agents such as ATRA and dimethyl sulfoxide have been
reported to induce granulocytic differentiation of HL-60 cells,
whereas 12-O-tetradecanoylphorbol-13-acetate and vitamin
D3 have been shown to induce their differentiation into
monocytes/macrophages [30]. The course of HL-60 cell dif-
ferentiation is accompanied by a number of changes in these
cells that can be monitored through morphological, histo-
chemical and immunological criteria. In addition to changes
in cell morphology, the generation of reactive oxygen species,
as measured by nitroblue tetrazolium (NBT)-reducing ability
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and expression of the αM protein subunit for the β2-integrin
(CD11b), are considered specific markers of HL-60 cell dif-
ferentiation [31]. It has been reported that undifferentiated
HL-60 cells either do not express or only weakly express
CD11b, while the expression of CD11b dramatically increases
when HL-60 cells have matured to the myelocyte level [32].
Several genetic alterations of specific oncogenes have been
also noted in HL-60 cells, including p53 deletion, c-myc am-
plification and Bcl-2 overexpression [33, 34]. In the present
study, we show for the first time that obatoclax, a pan-Bcl-2
inhibitor, promotes differentiation of human AML HL-60
cells accompanied by cell cycle arrest and the down-
regulation of Bcl-2 protein levels. Moreover, we demonstrate




Obatoclax mesylate (OBAT) was purchased from Selleck
Chemicals (Munich, Germany). The OBAT was dissolved in
DMSO and stored as 5 mM stock solutions at −20 °C. RPMI
1640 medium and fetal calf serum were obtained from
GIBCO BRL Life Technologies (Gaithersburg, MD, USA).
L-glutamine, antibiotic antimycotic solution (AAS), dimethyl
sulfoxide (DMSO), NBT, phorbol 12-myristate 13-acetate
(PMA) and anti-β-actin antibody (cat. #A5316) were pur-
chased from Sigma Aldrich (St. Louis, MO, USA). The
FITC Annexin VApoptosis Detection Kit I, propidium iodide
(PI)/RNase staining buffer and anti-CD-11b were obtained
from BD Biosciences (San Jose, CA, USA). The
CellEvent™ Caspase 3/7 Green Flow Cytometry Assay kit
was purchased from Molecular Probes (Eugene, OR, USA).
The Hemacolor® Rapid Staining kit was obtained from
Merck Millipore (Darmstadt, Germany). The antibody against
Bcl-2 (cat. #2876) and horseradish peroxidase-conjugated
secondary antibody (cat. #7074) were purchased from Cell
Signaling Technology (Danvers, MA, USA).
Cell culture and treatment
Human AMLHL-60 cells were obtained fromAmerican Type
Culture Collection (Rackville, USA). HL-60 cells were main-
tained in RPMI 1640 medium supplemented with 10% fetal
calf serum, 2 mM L-glutamine and AAS containing 20 units
of penicillin, 20 mg streptomycin and 0.05 mg amphotericin
B. The cells were passaged every third day. The cells grew
exponentially at 37 °C in an atmosphere of 5% CO2 in air
(HERAcell incubator, Thermo Fisher Scientific). Leukemic
cells were seeded in 12-, 24- or 96-well plates at a density of
1 × 105 cells/mL prior to performing the experiments. HL-60
cells were treated with OBAT at a concentration of either
100 nM or 500 nM. These clinically relevant concentrations
of OBAT were chosen based on previous studies [27]. The
control treatments consisted of untreated and DMSO-treated
HL-60 cells. The final concentration of DMSO did not influ-
ence the analyzed parameters and no significant differences in
the cell response to this diluent were observed, thus the data
obtained from DMSO-treated cells were considered the
control.
Cell cycle analysis
HL-60 cells were harvested by centrifugation, fixed with 70%
cold ethanol at 4 °C for 60 min and then stored at −20 °C until
analysis. Before staining with PI, the leukemic cell suspension
was washed twice with 1 ml of PBS. After washing, the cell
pellet was resuspended in 300 μl of the PI/RNase staining
buffer and the cells were incubated in the dark for 30 min at
room temperature. The red fluorescence of PI was measured
using a FACSCalibur flow cytometer (Becton Dickinson).
10,000 cells were examined in each sample. The percentages
of cell population that were in each phase of the cell cycle (G0/
G1, S, G2/M), as well as the frequency of sub-G1 population,
were calculated from the DNA content histograms using
WinMDI 2.8 software.
Assessment of cell differentiation
Analysis of leukemia cell morphology
An HL-60 cell suspension in PBS, containing approximately
1 × 105 cells, was added into a cytospin chamber and centri-
fuged at 1000 rpm for 6 min at 4 °C. After air drying, the
prepared cytospins were fixed in methanol for 15 min at room
temperature. The cytospins were stained with the
Hemacolor® Rapid Staining Kit according to the manufac-
turer’s instructions. The prepared cytospins were examined
under 100x magnification in a blinded manner by the same
observer, using an AXIO Scope.A1 microscope (Carl Zeiss,
Germany). Based on the morphological features of differenti-
ation, such as changes in cell size, alterations in the nuclear
shape and the nucleus/cytoplasm ratio [29], the percentage of
differentiated HL-60 cells was determined; 9000 leukemic
cells were counted in each treatment group (3000 cells per
slide).
Capacity to perform oxidative burst (NBT assay)
At the indicated time point, PMA at a final concentration of
100 nM was added to each well of a 96-well plate containing
100 μL of HL-60 cell suspension per well. The cells were
incubated with PMA at 37 °C for 60 min, after which 10 μL
of NBT solution (10 mg/mL) was added to each well and the
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cells were further incubated at 37 °C for 60min. Following the
incubation period, the cells were harvested by centrifugation
and cytospin slides were prepared. A light microscope was
used to identify NBT-positive cells that contained blue
formazan deposits. A total of 200 cells on each slide were
counted and the percentage of NBT-positive cells was calcu-
lated for each group.
Flow cytometric detection of CD11b expression
HL-60 cells were centrifuged, washed and resuspended in
100 μL of PBS. Then, 5 μL of either APC-conjugated
CD11b antibody or APC-conjugated isotype control antibody
was added to the suspension and the cells were incubated in
the dark for 30 min at room temperature. After the incubation
period, 400 μL of PBS was added to each tube and the cells
were centrifuged. Finally, the cells were resuspended in
500 μL of PBS and analyzed in the FACSCalibur flow
cytometer. 10,000 cells were examined in each sample and
the percentage of CD11b-positive cells was determined using
WinMDI 2.8 software.
Assessment of apoptosis
Detection of apoptosis by light microscopy
Microscopic quantitative assessment of apoptosis was per-
formed on cytospin slides prepared as described above and
performed simultaneously with the analysis of cell differenti-
ation. Based on the morphological features of apoptosis, such
as cell shrinkage, chromatin condensation and nuclear frag-
mentation, the apoptotic index was calculated as the percent-
age of apoptotic HL-60 cells identified among 9000 leukemic
cells (3000 cells per slide).
Annexin V-FITC/PI assay
Dual staining of HL-60 leukemic cells with fluorescein la-
belled annexin V (annexin V-FITC) and PI was performed
using the FITC Annexin VApoptosis Detection Kit I accord-
ing to the manufacturer’s instructions. Briefly, the cells were
washed twice with cold PBS and resuspended in 100 μl of the
binding buffer. Then, 5 μL of annexin V-FITC and 5 μL of PI
staining solution were added to the cell suspension and the
cells were incubated in the dark for 15 min at room tempera-
ture. Following the incubation, 400 μL of the binding buffer
was added to each tube. Cell samples were placed on ice away
from light and FITC and PI fluorescence was immediately
measured using the FACSCalibur flow cytometer. 10,000
cells were examined from each sample. The percentages of
annexin V-FITC+/PI− cells (early apoptotic cells) and annexin
V-FITC+/PI+ cells (late apoptotic and necrotic cells) were
determined using WinMDI 2.8 software.
Caspase activity assay
A CellEvent™ Caspase 3/7 Green Flow Cytometry Assay
Kit was used to detect activated caspases 3/7 in the leuke-
mic cells. HL-60 cells were centrifuged and suspended in
0.5 mL of PBS. Next, 0.5 μL of CellEvent® Caspase-3/7
Green Detection Reagent was added and the cells were
incubated for 30 min at 37 °C away from any light source.
The reagent fluorescence was immediately measured using
the FACSCalibur flow cytometer. 10,000 cells were exam-
ined from each sample and the percentage of cells with
active caspase 3/7 was determined using WinMDI 2.8
software.
Simultaneous detection of CD11b expression
and annexin V binding
After harvesting, the cells were centrifuged, washed with PBS
and suspended in 100 μl of annexin-V binding buffer. Then,
the cells were double-stained with 5 μL of APC-conjugated
anti-CD11b antibody and 5 μL of FITC-labeled annexin V for
30 min at room temperature. Following the incubation, the
cells were washed with PBS and analyzed by flow cytometry.
10,000 cells were examined from each sample and the per-
centage of CD11b+/annexin V-FITC+ cells was determined
using WinMDI 2.8 software.
Western blot analysis of Bcl-2 expression
Hl-60 cells were washed with ice-cold PBS and lysed in
ice-cold lysis buffer (50 mM Tris-HCl [pH 7.5] contain-
ing 100 mM NaCl, 0.5% sodium deoxycholate, 0.5%
NP-40, 0.5% SDS and protease inhibitors), and the ly-
sates were cleared by centrifugation at 15,000 g at 4 °C
for 30 min. Protein content was determined via a protein
assay using bovine serum albumin as a standard, after
which western blots for Bcl-2 were performed. Proteins
(30 μg from each experimental group) were separated by
Mini-PROTEAN® TGX™ gels (Cat. No. 456–1093;
BioRad), using SDS-PAGE (BioRad Mini-PROTEAN II
Electrophoresis Cell). Proteins were transferred to PVDF
membranes and incubated at 4 °C overnight with anti-
body diluted to 1:1000. Next, the membranes were incu-
bated with a horseradish peroxidase-conjugated second-
ary antibody diluted to 1:1000. Signals were detected by
chemiluminescence using the luminol reagent, visualized
using a ChemiDoc-It Imaging System (UVP, LLC,
Cambridge, UK) and quantified using ImageJ analysis
software (US National Institute of Health, Bethesda,
MD, USA). The blots were then stripped and probed
for anti-β-actin.
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Statistical evaluation
The obtained results were confirmed by two or three indepen-
dent experiments. All data are presented as the mean value ±
the standard deviation (SD). Statistical analyses were per-
formed using STATISTICA 10 (StatSoft, Kraków, Poland).
Statistical significance for the data was evaluated by one-
way analysis of variance (ANOVA) followed by Tukey’s hon-
estly significant difference multiple range test. A p value
<0.05 was considered statistically significant.
Results
Obatoclax affected HL-60 cell morphology
The effects of OBAT on the morphology of HL-60 cells was
studied over a time course of 72 h (Fig. 1a–c). After 24, 48 and
72 h, less than 10% of the untreated HL-60 cells were differen-
tiated. Exposure of HL-60 cells to OBAT resulted in morpholog-
ical changes characteristic of differentiation to the granulocytic
lineage, such as reduced cytoplasmic basophilia, reduced nuclear/
cytoplasmic ratio and the appearance of condensed and lobulated
nuclei; all cells fulfilling this criteria were considered to be in the
process of differentiation (Fig. 1a). Following 24 h of OBAT
application at concentrations of 100 nM and 500 nM, 20% and
38%ofHL-60 cells were differentiated, respectively. Exposure of
HL-60 cells to OBAT for 48 and 72 h further increased the
percentage of differentiated cells. The most pronounced morpho-
logical cell changes indicating differentiation were observed in
the cells exposed to the higher concentration of OBAT (500 nM),
which resulted in differentiation of 73% of the cells at the 72 h
time point (Fig. 1b), at which time most of the HL-60 cells were
observed to be in the metamyelocyte and band cell stages of
differentiation. Simultaneously, apoptotic morphology occurring
in HL-60 cells was noted to be both time- and dose-dependent.
Compared to the untreated control cells, the most significant
increase in the percentage of apoptotic cells was observed to
occur in HL-60 cells exposed to OBAT at a concentration of
500 nM. The apoptotic index in the control group was 0.6% at
the 72 h time point compared to 1.5% and 4% in the cells treated
with 100 nM and 500 nM of OBAT, respectively (Fig. 1c).
Obatoclax induced changes in the Bcl-2 protein level
In light of the key role of the Bcl-2 protein in hematopoietic
cell differentiation and apoptosis, we measured Bcl-2 activa-
tion in HL-60 cells exposed to OBAT. Compared to the con-
trol group, leukemic cells exposed to OBAT exhibited a re-
duced level of Bcl-2 expression. The results of western blot
analyses revealed 1.5- and 2-fold decreases in Bcl-2 protein
levels in leukemic cells following 48 and 72 h of treatment
with OBAT, respectively (Fig. 1d).
The effect of obatoclax on the cell cycle
Previously, we demonstrated that OBAT treatment significant-
ly decreased the number of HL-60 cells in a dose- and time-
dependent manner [27]. Because myeloid differentiation is
associated with a loss of proliferative capacity [35], in the
present study we investigated the effect of obatoclax on cell
cycle distribution. To accomplish this, HL-60 cells were
stained with PI and flow cytometric analysis of DNA content
was performed (Fig. 2a). Compared with the control values,
24 h of exposure to OBAT at a concentration of 500 nM re-
sulted in a marked accumulation of cells in the G0/G1 phase
accompanied with a significant reduction of cells in the G2/M
phase of cell cycle. Furthermore, treatment of cells with
500 nM of OBAT for 48 h decreased the percentage of cells
in the G0/G1 phase and further reduced the percentage of cells
in the S and G2/M phases of the cell cycle. Simultaneously to
these measurements, the percentage of the sub-G1 population
was found to be markedly increased. Treatment with OBATat
a concentration of 100 nM caused G0/G1 cell cycle arrest and
significantly increased the percentage of cells in the sub-G1
population at the 48 h time point (Fig. 2b, c).
Obatoclax promoted differentiation of HL-60 cells
To further verify the pro-differentiating effect of OBAT in HL-60
cells, we analyzed the cell surface expression of CD11b and
determined the ability of these cells to produce superoxide and
reduce NBT. As indicated in Fig. 3a, b, exposure of cells to
OBAT for 24, 48 and 72 h increased the number of cells express-
ing the CD11b antigen compared to their respective controls.
Approximately 4% of untreated HL-60 cells were CD11b-
positive at each time point while, following OBAT application
at concentrations of either 100 nM or 500 nM, 5% and 9% of
HL-60 cells were found to express the CD11b antigen after 24 h,
respectively. Longer incubations with OBAT increased the per-
centages of CD11b-positive cells. The highest percentage of
CD11b-positive cells, 31%, was found in cells exposed to
500 nM of OBAT for 72 h (Fig. 3b). Furthermore, a marked
time- and dose- dependent increase in the percentage of NBT-
positive cells occurred as a result of OBAT treatment. The NBT
reduction capability of HL-60 cells increased in a dose- and time-
dependent manner following treatment with OBAT. As such,
72 h of exposure to OBAT at concentrations of 100 nM or
500 nM resulted in 38% and 60% of the cells being NBT-posi-
tive, respectively (Fig. 3c).
Obatoclax enhanced apoptosis in HL-60 cells
In order to confirm that OBAT significantly increases
apoptosis of HL-60 cells, we tested the ability of
OBAT to trigger phosphatidylserine externalization, plas-
ma membrane disruption and caspase 3/7 activity in
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these cells. To achieve this, we used flow cytometry to
assess the percentage of early apoptotic cells, as well as
the percentage of HL-60 cells undergoing late apoptosis
and necrosis following treatment (Fig. 4a, b). As shown
in Fig. 4b, OBAT at a concentration of 100 nM signifi-
cantly increased cell death following both 24 and 48 h of
treatment. Treatment with OBAT at a concentration of
500 nM resulted in even more profound cell death, with
the most significant induction of apoptosis and necrosis
observed following treatment at this concentration for
72 h. Moreover, when comparing the values from HL-
60 cells exposed to OBAT at the highest concentration
(500 nM) for various time periods, a shift from early
apoptosis to late apoptosis and necrosis was noted be-
tween the 48 and 72 h time points. Following 48 h of
exposure to 500 nM of OBAT, 12% of HL-60 cells were
annexin V-FITC+/PI- and 3% were annexin V-FITC+/PI+
, whereas at the 72 h time point 9% of the cells were
found to be in the early apoptotic stage and 10% were in
the la te apoptot ic or necrot ic s tage (Fig. 4b) .
Fig. 1 Effects of obatoclax on the morphology of HL-60 cells and levels
of Bcl-2 protein in leukemic cells. aRepresentative images of HL-60 cells
treated with 100 or 500 nM of obatoclax (OBAT) for 48 h and stained
with Hemacolor demonstrating cells with characteristic features of differ-
entiation (scale bar = 20 μm). Quantitative assessment of differentiated
(b) and apoptotic (c) HL-60 cells performed under a light microscope. d
Western blot analysis of Bcl-2 protein expression performed 24, 48 and
72 h after leukemic cells were exposed to OBAT at a concentration of
500 nM. Relative levels of Bcl-2 protein were quantified by densitometry
and normalized toβ-actin. The results are expressed as the mean values ±
SD. Values significantly different (p ˂0.05) according to one-way
ANOVA are designated by: * compared to 24 h, ** compared to 48 h,
# compared to the corresponding control
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Accordingly, the activity of caspase 3/7 was significantly
increased in the HL-60 cells treated with 500 nM of
OBAT (Fig. 4c, d). The highest percentage of leukemic
cells with active caspase 3/7 was found in the group of
cells exposed to OBAT for 72 h (Fig. 4d).
Differentiation of HL-60 cells was associated
with the induction of apoptosis
In order to determine whether the apoptosis induced by
OBAT in HL-60 cells was associated with cell differen-
tiation, simultaneous detection of CD11b expression and
annexin V binding was performed in HL-60 cells ex-
posed to OBAT for 48 and 72 h (Fig. 5a). Compared
to the control group, treatment of HL-60 cells with
OBAT resulted in a significant increase in the percentage
of annexin V-FITC/CD11b-positive cells. The most pro-
nounced effect was observed at the 72 h time point, in
which 19% of cells were found to simultaneously exhibit
phosphatidylserine externalization and CD11b expression
(Fig. 5b). This observation suggests that, in a large por-
tion of the OBAT-treated cells, differentiation resulted in
apoptosis.
Discussion
The recent development of Bcl-2 inhibitors has offered a
novel therapeutic approach to treating cancer. As shown
by previous studies, compounds such as obatoclax, ABT-
737, ABT-199 and AT-101 exert potent pro-apoptotic ac-
tivity, thus making them valuable weapons in the fight
against cancer [36, 37]. Additional effects of Bcl-2 in-
hibitors on cancer cells beyond their role in triggering
apoptosis have been demonstrated, including the induc-
t ion of cell cycle arrest , the inhibit ion of cell






















Fig. 2 Effects of obatoclax on cell cycle distribution in HL-60 cells. a
Representative histograms of the cell cycle in leukemic cells analyzed 24
and 48 h after exposure to 100 or 500 nM of obatoclax. b Changes in the
percentage of HL-60 cells in specific phases of the cell cycle. c Changes
in the percentage of the sub-G1 population. The results are expressed as
the mean values ± SD. Values significantly different (p ˂0.05) according
to one-way ANOVA are designated by: * compared to 48 h, # compared
to the corresponding control
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proliferation and the induction of autophagy and necrotic
cell death [20, 38, 39]. A better understanding of the
mechanisms by which Bcl-2 antagonists exert their anti-
cancer action is of key importance for their further pre-
clinical and clinical development.
For the first time, our current study demonstrates the
pro-differentiating activity of the pan-Bcl-2 inhibitor
obatoclax in the HL-60 cell line, which is widely accept-
ed as a valuable model for studying the regulatory mech-
anisms of hematopoietic cell differentiation and apoptosis
[30]. The morphological and genetic characteristics of
HL-60 cells are well known, thus making these cells a
valid model for testing anti-leukemic compounds and in-
vestigating their mechanisms of action [29, 30, 40]. Our
results indicate that treatment of HL-60 cells with OBAT
induces dose- and time-dependent differentiation of these
leukemic cells. Following treatment with OBAT, HL-60
cells acquired a phenotype characteristic of more mature
myeloid cells, such as their specific morphology, the
ability to perform oxidative burst and higher expression
of CD11b, a myeloid differentiation marker. Together
with the induction of myeloid maturation, OBAT treat-
ment triggered dose- and time-dependent apoptosis in
HL60 cells, as determined through morphological chang-
es, increased percentages of annexin V-FITC-positive
cells and elevated numbers of cells with active caspase
3/7. Differentiation and apoptosis in HL-60 cells was
markedly increased by higher concentrations of OBAT,
indicating that the pro-differentiating effect of OBAT is
closely associated with its cytotoxicity. Previous studies
have demonstrated that, during differentiation, AML cells
undergo a number of marked changes in apoptosis-
related genes that make them more susceptible to the
apoptotic process [12, 40, 41]. The pro-apoptotic pheno-
type of these differentiated cells was shown to correlate
with a decreased expression of anti-apoptotic proteins of
the Bcl-2 family. The down-regulation of anti-apoptotic
Bcl-2 proteins during myeloid differentiation has been
well established [12, 42]. Decreased expression of Bcl-
2 proteins appears to be part of the differentiation path-
way and may serve to facilitate the apoptotic response
[12]. Studies have shown that HL-60 cells induced to
differentiate into neutrophils down-regulate Bcl-2 [43],
an observation that is consistent with the findings from
our study. We first noted suppression of Bcl-2 expression
48 h after HL-60 cells were exposed to OBAT, correlat-
ing with increased cell differentiation and apoptosis and
suggesting that decreased Bcl-2 expression may be one
of the events triggering the apoptosis in these cells. Of
note, the pro-differentiating drug ATRA has been shown
to repress Bcl-2 mRNA in differentiated AML cells [44,
45]. However, the differentiation of HL-60 cells exposed
to OBAT could also partially occur through Bcl-2-
independent mechanisms. Previous studies have shown
that the over-expression of Bcl-2 in HL-60 cells sup-
presses apoptosis without producing any effects on the
differentiation process [46]. Moreover, although many
studies have shown down-regulation of anti-apoptotic
Bcl-2 proteins following obatoclax treatment [19, 22],
recent studies have indicated that obatoclax can also act
through other cellular targets, such as p38/p21 [26] and
mTOR [47] signaling pathways. Additional experiments
are needed to firmly establish the role of Bcl-2 in
obatoclax-induced differentiation of HL-60 cells.
Evident temporal changes in the percentages of differ-
entiated and apoptotic HL-60 cells observed in the pres-
ent study indicated that the restoration of apoptotic po-
tential may be associated with progression of differenti-
ation. To investigate this further, we co-stained HL-60
cells for annexin V and CD11b and observed that a large
proportion of the differentiated cells were undergoing
apoptosis; this was especially evident following longer
durations of OBAT treatment (72 h). This observation
is in agreement with previous findings showing that cul-
tures of terminally differentiated myeloid leukemia cells
contain a proportion of apoptotic cells [30, 48], which is
especially noted after longer incubation periods of mye-
loid cells with differentiation inducers [46, 49]. However,
it has also been reported that maturation of AML cells is
not always necessary for triggering apoptosis [46], in fact
differentiation and apoptosis can occur as separate events
under different regulation in AML cells [50]. Therefore,
it is noteworthy that differentiation of HL-60 cells fol-
lowing OBAT treatment may occur both simultaneously
and independently of cell death, although further analysis
is needed to clarify if this situation occurs in AML cells.
Previous in vitro studies have demonstrated that
obatoclax’s anti-leukemic activity in AML cell lines
and primary AML samples involves decreased cell pro-
liferation [19]. Consistent with this data, the ability of
OBAT to promote HL-60 maturation in the current study
was shown to be coupled to cell cycle arrest in the G0/
G1 phase. This cell cycle regulating property of
obatoclax, via G1 phase arrest, has also been demonstrat-
ed in human colorectal [25, 51], esophageal [26] and
thyroid [52, 53] cancer cells. As shown by Wei et al.,
Fig. 3 Effects of obatoclax on the differentiation of HL-60 cells evaluated
24, 48 and 72 h after treatment at concentrations of 100 nM and 500 nM.
a Representative histograms of CD11b expression on HL-60 cells mea-
sured by flow cytometry 72 h after leukemic cell exposure to obatoclax. b
The percentages of CD11b-positive HL-60 cells. c Changes in the per-
centages of cells performing oxidative burst (NBT-positive cells). The
results are expressed as the mean values ± SD. Values significantly dif-
ferent (p ˂0.05) according to one-way ANOVA are designated by: *
compared to 24 h, ** compared to 48 h, # compared to the corresponding
control
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exposure of thyroid cancer cells to obatoclax resulted in
enrichment of cells in the G0/G1 phase accompanied
with decreased cells in the S and G2/M phases in a
concentration-dependent manner [53]. Cell cycle arrest
induced by obatoclax was found to be correlated with
reduced expression of cyclin D1 [51, 53]. Moreover,
the delayed cell cycle of colorectal cancer cells was not
influenced by over-expression of pro-survival Bcl-2 pro-
teins [25]. These findings suggest that obatoclax’s effect
on the cell cycle is Bcl-2 independent. Previous studies
have demonstrated that the most pronounced effect Bcl-2
has on the cell cycle is to delay the progression from G0/
G1 phases to S phase [54, 55]. Therefore, direct inhibi-
tion of Bcl-2 should facilitate G1/G0 to S phase transi-
tion instead of inducing G1/G0 phase arrest. This con-
sideration indicates that non-canonical signaling
pathways may be targeted by obatoclax. Moreover, the
correlation between cell cycle arrest and AML cell dif-
ferentiation following obatoclax treatment must be fur-
ther established. In the present study, cell cycle arrest
in the G0/G1 phase along with reduction of G2/M phase
cell populations, was observed 24 h after HL-60 cell
treatment with OBAT while a substantial increase in the
percentage of differentiated cells was noted 48 h after
treatment. Based on these results, it can be proposed that
the cell cycle arrest induced by OBAT contributes to its
pro-differentiation activity.
In conclusion, our study has shown for the first time that
obatoclax, a small-molecule inhibitor of the Bcl-2 protein
family, promotes maturation of HL-60 cells. This pro-
differentiation effect was associated with the ability of
obatoclax to induce cell cycle arrest and apoptosis in AML
cells. Aside from obatoclax, it is worth noting that gossypol,
another pan-Bcl-2 inhibitor, has also been shown to induce
differentiation in leukemic cells [56]. Therefore, the anti-
leukemic effects of Bcl-2 inhibitors may be more complex
than thus far determined. It can be assumed that the anti-
AML activity of obatoclax involves the induction of differen-
tiation as well as apoptosis. However, further mechanistic
studies will be required to establish which differentiation and
cell death pathways are involved. Nevertheless, the pro-
differentiation activity of obatoclax offers a new promising
treatment approach for AML that merits further studies.
















Fig. 5 CD11b expression and annexin-V binding by obatoclax-treated
HL-60 cells. Cells were exposed to 500 nM of obatoclax (OBAT) for
48 and 72 h and analyzed by flow cytometry. a Representative flow
cytometry dot plots showing HL-60 cells stained with annexin V-FITC
and CD11b. b Changes in the percentages of double positive cells for
annexinVand CD11b. The results are expressed as themean values ± SD.
Values significantly different (p ˂0.05) according to one-way ANOVA
are designated by: * compared to 48 h, # compared to the corresponding
control
Fig. 4 Effect of obatoclax on the induction of apoptosis in HL-60 cells. a
Representative flow cytometry dot plots showing HL-60 cells stained
with annexin V-FITC and propidium iodide (PI). b Changes in the per-
centages of early apoptotic cells (annexin V-FITC positive/PI negative)
and late apoptotic and necrotic cells (annexin V-FITC positive/PI posi-
tive) were assessed 24, 48 and 72 h after leukemic cells were treated with
obatoclax (OBAT) at concentrations of 100 nM and 500 nM. c
Representative histograms of caspase 3/7 activation measured by flow
cytometry 72 h after leukemic cell exposure to OBAT. d The percentage
of HL-60 cells with active caspase 3/7 was determined 24, 48 and 72 h
after cell exposure to 500 nM of OBAT. The results are expressed as the
mean values ± SD. Values significantly different (p ˂0.05) according to
one-way ANOVA are designated by: * compared to 24 h, ** compared to
48 h, # compared to the corresponding control
R
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